For Immediate Release:  
November 2, 2005

Contact:  
Jessica Sandler 757-622-7382, ext. 8001; JessicaS@peta.org  
Holly Mattern 757-622-7382, ext. 8340

PETA-BACKED RESOLUTION TO END BARR PHARMACEUTICALS ANIMAL TESTS GOES TO SHAREHOLDER VOTE  
Stockholders to Be Presented With Effective, Humane Alternatives

Woodcliff Lake, N.J. — Backed by PETA, a shareholder of Barr Pharmaceuticals (the parent company of drugmaker Barr Labs) has introduced a resolution that will be voted on at the company’s annual meeting in Woodcliff Lake on Thursday. The resolution calls on the company to replace five painful animal tests with effective, state-of-the-art, non-animal test methods that are currently available and in use in the European Union, Canada, and other countries:

Date: **Thursday, November 3**  
Time: **10 a.m.**  
Place: **Woodcliff Lake Hilton, 200 Tice Blvd.**

The resolution is part of PETA’s “Give the Animals 5” Campaign, which seeks to end the use of rabbits and other animals in tests that involve injecting animals with drugs or applying chemicals to their shaved skin. More effective non-animal test methods using human cells and human blood are available.

Working with a number of its members, PETA filed similar resolutions in 2005 with 18 of the largest chemical and pharmaceutical companies in the United States. Five companies—Dow Chemical, GE, Johnson & Johnson, 3M, and Schering-Plough—filed appeals with the Securities and Exchange Commission (SEC), arguing that the resolutions should be declared ineligible for consideration by their stockholders, but the SEC rejected the arguments and ruled that the companies must include the PETA-sponsored animal-testing resolutions in their proxy materials. The filings have led to productive discussions between PETA’s science advisors and several of the companies. PETA agreed to withdraw its resolutions from Johnson & Johnson, ExxonMobil, Schering-Plough, Dow, and Medtronics following negotiations.

“Shareholders have a right to vote on an issue that affects their investment,” says PETA Vice President Mary Beth Sweetland. “When expensive, outdated, and unreliable animal tests are used instead of relevant high-tech, humane, non-animal test methods, shareholders end up paying the price.”

A copy of the resolution is available upon request. For more information, please visit PETA’s Web site StopAnimalTests.com.

#